Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
28 Cards in this Set
- Front
- Back
causes of increased gram positive bacteremia in neutropenic patients (4)
|
-indwelling IV catheters
-increased rates of mucositis -less gram + empiric coverage -prophylaxis w/ antimicrobias providing gram + coverage |
|
most frequently occurring leukocyte; number of days for production and differentation in bone marrow; avg time in circulation; turnover
|
neutrophil;14d;6-12hr;BID
|
|
fever definition
|
oral temp of >101F or 100.4F >= 1hr
|
|
normal range neutrophils
|
1,800-7800 neutrophils/mm3
|
|
ANC formulas (2)
|
- WBC x [(%segs/100) + (%bands/100)]
- WBC x (%neutrophil/100) WBC x 10^3 |
|
mild; moderate; severe ANC's
|
<1000/mm3; <=500/mm3; <100/mm3
|
|
what diseases affect neutrophil phagocytic function increasing risk of infection?
|
leukemia, lymphoma
|
|
low risk stratification (5)
|
-ANC >=100
-neutropenia <=7d -neutropenia resolution w/in 10d -normal chest radiograph -peak temp <102F |
|
signs of infection in a neutropenic patient
|
-fever
-pain at IV sites |
|
neutropenic patient baseline workup (7)
|
-CXR
-BMP -CBC w/ differential -LFTs -urinalysis w/ culture -physical exam ->=2 blood samples for culture from different sites |
|
gram + pathogens (5)
|
-staph aureus
-strep viridans -enterococcus -corynebacterium -bacillus |
|
gram - pathogens (6)
|
-pseudomonas
-klebsiella -e.coli -enterobacter -proteus -stenotrophomonas |
|
when to start antibiotics (2)
|
-onset of fever
-if patient is afebrile w/ ANC <=500 (or 1000 and trending down) presenting w/ s/sx of infection |
|
outpatient empiric therapy
|
cipro AND augmentin
|
|
inpatient empiric therapy
|
-cefepime OR ceftazidime OR a carbapenem
-aminoglycoside AND antipseudomonal penicillin OR ceftazidime OR cefepime OR a carbapenem |
|
When should vancomycin empirically be used
|
-strep viridans suspected
-catheter related infection -+ culture w/ a gram + pathogen but before sus. test -MRSA -hypotension/cardiovasular impairment -mucosal damage from chemo -progression to infection from previously classified low risk or previous px w/ a FQ |
|
afebrile w/in 3 days of tx
|
-tailor therapy to pathogen if identified
-cont antib x7d t prevent breakthrough infection, until - cultures, sites of infection resolved, and pt is free from s/sx x7d -preferable to have ANC >500 b4 discontinuing antibiotics |
|
febrile >3d
|
-consider non-bacterial infection, resistance, slow response, 2nd infection, drug fever, avascular infection
-pt may be fine, avg defervescence may take 5d -reassess pt w/ CXR, organ imaging, etc |
|
when should empiric antifungal therapy be started?
|
initiate at 5-7d if patient continues to be febrile and severely neutropenic despite treatment w/ broad spectrum antibiotics
|
|
duration of antifungal therapy
|
continue for 14d in absence of infections s/sx
|
|
gold standard antifungal therapy
|
amphoterecin B 0.5-1mg/kg/d
|
|
amphoterecin B adverse effects
|
-nephrotoxicity
-infusion related reactions -breakthrough fungal infections |
|
fluconazole indications
|
-used only at institutions w/o drug resistant candida spp.
|
|
fluconazole cannot be used in patients with: (2)
|
-suspected aspergillus infection
-BMT pts who received px w/ fluconazole |
|
what is the single most important determinant of antibiotic discontinuation?
|
neutrophil count
|
|
when can theraptay be d/c
|
generraly when ANC >500 x2d if no infectious lesions are identified despite continued febrile state
-continue antibiotics if pt has ANC <100 OR lesions on mucous membranes/GI tract OR unstable vital signs |
|
when is prophylaxis warranted?
|
against pnemocystis jerovecii in some neutropenic pts, such as those w/ hematologic malignancies due to additional risk of cell phagocytic defects
|
|
health care precautions (5)
|
-reverse isolation
-hand washing -avoid fresh fruits and vegetables -laminar flow hoods to filter air away from pt -well cooked food |